Powered by: Motilal Oswal

News

Syngene International shines on reporting 21% rise in Q4 consolidated net profit Syngene International is currently trading at Rs. 643.70, up by 20.25 points or 3.25% from its previous closing of Rs. 623.45 on the BSE. The scrip opened at Rs. 640.00 and has touched a high and low of Rs. 659.80 and Rs. 632.00 respectively. So far 113723 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 659.80 on 27-Apr-2022 and a 52 week low of Rs. 511.50 on 26-May-2022. Last one week high and low of the scrip...
Syngene International shines on reporting 21% rise in Q4 consolidated net profit
Syngene International shines on reporting 21% rise in Q4 consolidated net profit
Source: Accord Fintech
27/04/2023 2:29:22 PM
Syngene Internationa Q3 net profit up 5.90% at Rs 109.50 cr The company reported standalone net profit of Rs 109.50 crore for the quarter ended December 31, 2022 as compared to Rs 103.40 crore in the same period last year, registering a year-on-year growth of 5.90 per cent. Net revenue of the company rose substantially by 23.00 per cent at Rs 786.60 crore in October-December quarter of this fiscal as against Rs 639.50 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 27.31 per cent to Rs 556....
Syngene Internationa Q3 net profit up 5.90% at Rs 109.50 cr
Syngene Internationa Q3 net profit up 5.90% at Rs 109.50 cr
Source: Dion Global Services Ltd.
24/01/2023 12:02:11 PM
Sell Syngene International Ltd For Target Rs.520 - Yes Securities Lack of revenue catalysts Result Synopsis Syngene clocked a robust quarter with 25% YoY growth aided by forex tailwind of ~8% compared to last year leading to an underlying operational growth of ~17% YoY. Growth was across the board and driven by discovery services and dedicated centres. Growth in drug development vertical was led by existing client renewals and setting up collaboration on additional projects. Deal for Zoetis product manufacturing remains on track and Syngene expects a...
Sell Syngene International Ltd For Target Rs.520 - Yes Securities
Sell Syngene International Ltd For Target Rs.520 - Yes Securities
Source: Yes Securities Ltd
21/10/2022 11:45:48 AM
Syngene International rises on incorporating wholly owned subsidiary Syngene International is currently trading at Rs. 602.65, up by 1.55 points or 0.26% from its previous closing of Rs. 601.10 on the BSE. The scrip opened at Rs. 585.25 and has touched a high and low of Rs. 611.95 and Rs. 585.25 respectively. So far 23566 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 686.00 on 15-Sep-2021 and a 52 week low of Rs. 508.10 on 22-Feb-2022. Last one week high and low of the scrip s...
Syngene International rises on incorporating wholly owned subsidiary
Syngene International rises on incorporating wholly owned subsidiary
Source: Accord Fintech
29/08/2022 2:10:42 PM
Syngene International gains on inking pact to acquire 26% stake in O2 Renewable Energy II Syngene International is currently trading at Rs. 605.90, up by 4.80 points or 0.80% from its previous closing of Rs. 601.10 on the BSE. The scrip opened at Rs. 585.25 and has touched a high and low of Rs. 605.90 and Rs. 585.25 respectively. So far 3349 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 686.00 on 15-Sep-2021 and a 52 week low of Rs. 508.10 on 22-Feb-2022. Last one week high and low of the scrip st...
Syngene International gains on inking pact to acquire 26% stake in O2 Renewable Energy II
Syngene International gains on inking pact to acquire 26% stake in O2 Renewable Energy II
Source: Accord Fintech
29/08/2022 10:27:21 AM
Syngene International soars on signing 10-year biologics manufacturing agreement with Zoetis Syngene International is currently trading at Rs. 610.20, up by 23.15 points or 3.94% from its previous closing of Rs. 587.05 on the BSE. The scrip opened at Rs. 602.95 and has touched a high and low of Rs. 612.50 and Rs. 593.25 respectively. So far 37679 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 699.95 on 16-Jul-2021 and a 52 week low of Rs. 508.10 on 22-Feb-2022. Last one week high and low of the scrip ...
Syngene International soars on signing 10-year biologics manufacturing agreement with Zoetis
Syngene International soars on signing 10-year biologics manufacturing agreement with Zoetis
Source: Accord Fintech
15/07/2022 10:29:52 AM
Syngene International rises on inking agreement to acquire equity stake up to 26% in AREREPL Syngene International is currently trading at Rs. 575.20, up by 4.30 points or 0.75% from its previous closing of Rs. 570.90 on the BSE. The scrip opened at Rs. 572.55 and has touched a high and low of Rs. 575.50 and Rs. 572.25 respectively. So far 1368 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 699.95 on 16-Jul-2021 and a 52 week low of Rs. 508.10 on 22-Feb-2022. Last one week high and low of the scrip st...
Syngene International rises on inking agreement to acquire equity stake up to 26% in AREREPL
Syngene International rises on inking agreement to acquire equity stake up to 26% in AREREPL
Source: Accord Fintech
13/07/2022 10:28:24 AM
Weekly Tech Picks - Bharat Electronics , SBI Life Insurance, Steel Authority of India Limited, Syngene International Limited By Axis Securities Bharat Electronics • On the weekly chart, the stock has decisively broken out its past eight months “Consolidation Range” (230- 195) on a closing basis indicating strong come back of bulls • This buying momentum was observed from 20, 50 and 100 day SMA and rebounded sharply Bharat Electronics Limited Weekly Tech Picks 08 April,2022 • With current week’s high (242) the stock has registered a new 52-week high which remains a bullish signal • The...
Weekly Tech Picks - Bharat Electronics , SBI Life Insurance, Steel Authority of India Limited, Syngene International Limited By Axis Securities
Weekly Tech Picks - Bharat Electronics , SBI Life Insurance, Steel Authority of India Limited, Syngene International Limited By Axis Securities
Source: Axis Securities Ltd
11/04/2022 10:45:22 AM
Sell Syngene International Ltd For Target Rs.515 - Yes Securities An inline Q; lack of near term surprise keeps us away Our view Improvement in guidance from mid‐teens to high teens in FY22 is an acknowledgement of the 21% growth so far in 9m FY22. However, if we remove Remdesivir’ contribution in Q1, growth for FY22 does appear underwhelming in the 14% ball park. Margins have been trended lower in 9m so far (Q1 impact due to lower gross margin in Remdesivir) but expect these to rebound in Q4 and FY23 onwards. Expect revenue growth in the rage o...
Sell Syngene International Ltd For Target Rs.515 - Yes Securities
Sell Syngene International Ltd For Target Rs.515 - Yes Securities
Source: Yes Securities Ltd
24/01/2022 9:48:32 AM
Sell Syngene International Ltd For Target Rs.520 - Yes Securities Lack of near term triggers Our view Management commentary remains positive around demand environment particularly for clients based out of US & Europe though the company refrained from changing revenue guidance. Albeit, overstocking on RM that need to be expensed to have a toll on gross margin which we now cut by 300bps vs our previous estimate of 75% ; coupled with Rs310mn in one‐time write down of export incentives, leads to a 24% cut to FY22 EPS. However, FY23/24 estimates rem...
Sell Syngene International Ltd For Target Rs.520 - Yes Securities
Sell Syngene International Ltd For Target Rs.520 - Yes Securities
Source: Yes Securities Ltd
22/10/2021 9:18:11 AM
Buy Syngene International Limited Target Rs.645 - Religare Broking Derivative Ideas  SYNGENE FUTS added around 5% in open interest in as LONG buildup was seen in it. Current chart pattern also indicates further up move in its price. We suggest buying in SYNGENE as per below levels. Strategy:- BUY SYNGENE BETWEEN 622-625 SL 610 TARGET 645.   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330   ...
Buy Syngene International Limited Target Rs.645 - Religare Broking
Buy Syngene International Limited Target Rs.645 - Religare Broking
Source: Religare Broking Ltd
13/09/2021 11:05:24 AM
Buy Syngene International Ltd Target Rs.675 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Above views are of the author and not of the website kindly read disclaimer
Buy Syngene International Ltd Target Rs.675 - Religare Broking
Buy Syngene International Ltd Target Rs.675 - Religare Broking
Source: Religare Broking Ltd
1/09/2021 12:09:37 PM
Buy Syngene International Ltd For Target Rs.780 - ICICI Direct Mixed numbers; Remdesivir impacts margins… About the stock: Syngene is an innovation-led contract research, development and manufacturing organisation offering integrated scientific services from early discovery to commercial supply. * It is one of the largest listed contract research organisations (CRO) in India * Revenue breakup: Discovery services (35%), dedicated services (32%), development and manufacturing (33%)   Q1FY22 Results: Syngene reported mixed Q1FY22 ...
Buy Syngene International Ltd For Target Rs.780 - ICICI Direct
Buy Syngene International Ltd For Target Rs.780 - ICICI Direct
Source: ICICI Direct
11/08/2021 12:08:00 PM
Quote on Syngene international reported a weak set of numbers for Q1FY2022 by Mr. Yash Gupta, Angel Broking Ltd Below is quote on Syngene international reported a weak set of numbers for Q1FY2022 by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd    Syngene international reported a weak set of numbers for Q1FY2022.  Syngene international limited reported revenue from operation at ₹595.4 crores up by 41% as compared to ₹421.6 crores in Q1FY21. EBITDA was at ₹177.3 crores up by 27% as compared to ₹139.8 crores in Q1FY21 and reported EBI...
Quote on Syngene international reported a weak set of numbers for Q1FY2022 by Mr. Yash Gupta, Angel Broking Ltd
Quote on Syngene international reported a weak set of numbers for Q1FY2022 by Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
22/07/2021 12:05:38 PM
Sell Syngene International Ltd For Target Rs. 515 - Yes Securities Our view After an outsized Remdesivir sales boost in Q1 and no change to 15% revenue growth guidance in FY22, rest of the fiscal translates into just 8‐9% yoy growth. Also 20% capacity utilization of Mangalore facility in 2 years results in 2% annual revenue boost in FY22/23. Hence, we view absolute contribution of Mangalore API facility as insignificant given the base in FY23. Another potential catalyst in the form of API supply for Alberio is also baked in the guidance and we believe any...
Sell Syngene International Ltd For Target Rs. 515 - Yes Securities
Sell Syngene International Ltd For Target Rs. 515 - Yes Securities
Source: Yes Securities
22/07/2021 10:45:33 AM
Buy Syngene International Ltd For Target Rs. 700 - ICICI Direct Growth trajectory maintained, outlook upbeat… FY21 revenues grew 8.6% YoY to | 2184 crore driven by steady growth across all divisions. Adjusting for loss of export incentives, revenues grew 12% in FY21. EBITDA margins remained flat YoY at 30.8% with better gross margins being offset by higher employee cost amid higher headcount. EBITDA grew 8.7% YoY to | 672 crore. Adjusted PAT grew 4.4% YoY to | 382 crore. Delta vis-a-vis EBITDA was due to higher depreciation and lower other incom...
Buy Syngene International Ltd For Target Rs. 700 - ICICI Direct
Buy Syngene International Ltd For Target Rs. 700 - ICICI Direct
Source: ICICI Direct
3/05/2021 9:59:48 AM
Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges BENGALURU  - India's Syngene International Ltd aims to supply half-a-million vials of COVID-19 drug remdesivir through its local distribution partners next month, its top executive said, as the country faces shortages of the medicine amid a second wave. "At the moment we are operating at near maximum capacity (to produce remdesivir)," Chief Executive Officer Jonathan Hunt told Reuters on Wednesday. "I'd expect the volume of drug that we are supplying into the...
Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges
Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges
Source: Reuters
29/04/2021 9:34:45 AM
Sell Syngene International Ltd For Target Rs. 400 - Yes Securities Result Highlights * FY22 guidance – Mid teens growth in revenues. EBIDTA margin expected to stay flat at around 30%. Investment‐led growth to result in single digit profit growth. Capex of Rs7.5‐9bn.   * Single digit growth in FY22 PAT (excluding exceptional items) leads to 12% cut in ours and even more so for consensus FY22 estimates * Healthy end to FY21 with underlying revenue +13%, excluding export incentives. Growth driven by discovery, manufacturing and dedicate...
Sell Syngene International Ltd For Target Rs. 400 - Yes Securities
Sell Syngene International Ltd For Target Rs. 400 - Yes Securities
Source: Yes Securities Ltd
29/04/2021 9:03:48 AM
Sell Syngene International Ltd For Target Rs.400 - Yes Securities Our View * Revenue acceleration from Mangalore API manufacturing may be back ended beyond FY23, especially as company guides to a 3‐5 year start up period * Expect margins to inch up in FY23 as 200bps Mangalore cost inbuilt in current opex while revenues to start in FY23 * Build in 18%/22% growth in FY22/23 with contribution starting from Mangalore plant * Remain 7% below consensus on FY22 and 4% below for FY23 estimates as we build in slower Mangalore ramp up * Roll over 26x ...
Sell Syngene International Ltd For Target Rs.400 - Yes Securities
Sell Syngene International Ltd For Target Rs.400 - Yes Securities
Source: Yes Securities Ltd
22/01/2021 9:21:43 AM
Quote on Syngene Ltd By Yash Gupta, Angel Broking Ltd Below are Quote on Syngene Ltd By Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd “Syngene reported numbers in line with the expectation. Syngene international Ltd total revenue from operations for Q3FY21 stood at ₹584.5 crores up by 13% YoY from ₹519.1 crores in Q3FY20. EBITDA for Q3FY21 stood at   ₹193 crores up by 11% as compared to ₹173.5 crores in Q3FY20. EBITDA margins are same as Q3FY20.   Profit after tax for the quarter up by 11% at ₹102...
Quote on Syngene Ltd By Yash Gupta, Angel Broking Ltd
Quote on Syngene Ltd By Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
21/01/2021 3:31:47 PM
Syngene Internationa Q3 net profit up 11.14% at Rs 101.80 cr The company reported standalone net profit of Rs 101.80 crore for the quarter ended December 31, 2020 as compared to Rs 91.60 crore in the same period last year, registering a year-on-year growth of 11.14 per cent. Net revenue of the company rose moderately by 12.52 per cent at Rs 584.10 crore in October-December quarter of this fiscal as against Rs 519.10 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 11.61 per cent to Rs 408....
Syngene Internationa Q3 net profit up 11.14% at Rs 101.80 cr
Syngene Internationa Q3 net profit up 11.14% at Rs 101.80 cr
Source: Dion Global Solutions Ltd
21/01/2021 11:27:11 AM